When the new crown drug concept stock, Fuxiang Pharmaceutical's 20CM rise and stop was accurately cashed out by Yongtai Technology, will it fall sharply?

Reporter | Wu Zhibang

Edit |

In recent trading days, companies that supply raw materials for the new crown drugs have performed well, and Yaben Chemical (300261.SZ) has suspended trading due to continuous sharp rises. Fuxiang Pharmaceutical (300497.SZ), which focuses on the development and production of APIs, disclosed the information on research activities on the evening of January 19, showing that the company supplies mopiravir and remdesivelde core intermediates to customers, which can be used to treat new crown pneumonia.

Public information shows that as an important company in the API industry, Fuxiang Pharmaceutical's products and business are mainly divided into two categories: 1, to high-end antibiotic APIs and their intermediates research and development, production and sales as the main business, the products mainly include sulbactam series, tazobactam series of β-lactamase inhibitor APIs and intermediates, carbapenem (Penem series) antibacterial drug APIs and intermediates; 2, engaged in the research and development, production and sales of antiviral drug intermediates, products mainly include lovir series, Intermediate products such as navir series products have become one of the major suppliers of lovir drug intermediates in the world. Weifang Aotong, a holding subsidiary, is the company's antiviral drug production platform.

In the research records disclosed on the evening of January 19, Fuxiang Pharmaceutical claimed to institutional investors that the company currently supplies customers with mopiravir and remdesivir core intermediates, which can be used to treat new crown pneumonia. Because the company has signed a strict confidentiality agreement with the customer, it is inconvenient to disclose specific customer information. Moreover, the above-mentioned related intermediate products currently account for a relatively small proportion of revenue and have not had a significant impact on the company's performance.

In addition, Fuxiang Pharmaceutical further told the institution in the above research record that since the company acquired Weifang Aotong in 2016, the anti-virus field has gradually become one of the important business areas of the company. Based on the company's subsidiaries have rich experience in the production of antiviral pharmaceutical intermediates and strong commercial production capacity, the company is constantly strengthening research and development, and cooperates with Lingfu Pharmaceutical Research Institute, and now has the production capacity of new crown therapeutic drug intermediates research and development, and the company expects to be able to enter the supply chain system of new crown therapeutic drug production of Pfizer and other companies.

In fact, in the investor interaction on the morning of January 19, Fuxiang Pharmaceutical intensively replied to the supply of new crown drug intermediates. However, Fuxiang Pharmaceutical was surveyed by institutional investors on January 18, and the participants included Southwest Securities, Huaan Fund, E Fund, Great Wall Fund, Bank of China Fund, Huashang Fund, Wanjia Fund, Bosera Fund, Oriental Alpha, Minsheng Plus Bank, Huaxia Fund, BOCOM Schroders, Shanghai Xitai Investment and other institutions, in the form of online teleconference.

From the perspective of secondary market performance, in the early trading of January 19, in the context of the sharp decline in peripheral pharmaceutical manufacturing stocks, the stock price of Fuxiang Pharmaceutical did not perform. However, after the opening of the market on the afternoon of January 19, Fuxiang Pharmaceutical was blocked by a large buy order, and as of the close of january 19, there were still 380 million yuan of buy orders hanging on the up and down board.

According to the data of the Dragon and Tiger List, The Shenzhen Branch of East Asia Qianhai Securities, the Securities Business Department of Industrial Securities Shanghai Expo Pavilion Road, the Securities Sales Department of Oriental Securities Shanghai Pudong New Area Yuanshen Road, the Meihua Road Securities Business Department of Guojin Securities Shanghai Pudong New Area, and the Securities Business Department of CITIC Securities Shanghai Dongfang Road were among the top five business departments to buy, with net purchases of 102.90 million yuan, 60.5388 million yuan, 48.8376 million yuan, 42.4306 million yuan and 31.0036 million yuan respectively.

It is worth mentioning that Yongtai Technology (002326.SZ), a shareholder of Fuxiang Pharmaceutical, reduced its holdings on January 19, with the number of shares reduced to 2,507,040 shares, and the average price of the reduction was 21.30 yuan per share.

On January 20, Fuxiang Pharmaceutical's stock price fell back after the opening limit, closing down 7.31%.